{
  "abstract": "The determination of benefit for mechanical thrombectomy (MT) in emergent large vessel occlusion (ELVO), as demonstrated through randomized controlled trials (RCTs), has been a tumultuous process over the last decade and a half. In 2013, three trials were published in the New England Journal of Medicine (NEJM,) each demonstrating no benefit for MT for ELVO.1–3 These results were reflected in the 2013 American Heart Association (AHA) guidelines4 and led to significant doubt in the medical community as to whether MT would ever prove effective for patients with ELVO.5 However, these trials had numerous limitations, including a failure to select patients with ELVO with vascular imaging, delays in reperfusion, and inadequate thrombectomy devices.",
  "authors": [
    {
      "affiliations": [
        "Neurosurgery, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA"
      ],
      "name": "Justin R Mascitelli"
    },
    {
      "affiliations": [
        "Neurosurgery, Weill Cornell Medical College, New York, New York, USA"
      ],
      "name": "J Mocco"
    }
  ],
  "title": "A response to the 2026 stroke guidelines with a focus on endovascular treatment of medium and distal vessel occlusions",
  "uid": "f9027022-0bbc-58e3-b623-b5aee2c6b128"
}